Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to its existing Moderna Technology Center ("MTC") in Norwood, Massachusetts. Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the U.S. This milestone marks a significant step in strengthening Moderna's U.S. manufacturing network, supporting both commercial and clinical supply, and reinforcing the Company's commitment to domestic mRNA production. "By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," said Stéphane Bancel, Chief Executive Officer of Moderna. "As an American company committed to building and producing in America
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) was given a new $18.00 price target on by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Royal Bank Of Canada from $28.00 to $25.00. They now have a "sector perform" rating on the stock.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 12/1/25 - Form 4
- MRNA's page on the SEC website